Compare
Akebia Therapeutics, Inc. vs Puma Biotechnology, Inc. vs Schrodinger, Inc. vs Harrow, Inc.
| Latest fiscal year | Akebia Therapeutics, Inc. AKBA | Puma Biotechnology, Inc. PBYI | Schrodinger, Inc. SDGR | Harrow, Inc. HROW |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $236.20M | $228.37M | $255.87M | $272.30M |
| Revenue growth (YoY) | +47.5% | -0.9% | +23.3% | +36.4% |
| Gross margin | 83.3% (computed) | 74.5% (computed) | 55.7% | 75.1% |
| Operating margin | 9.9% | 16.3% | -65.2% | 11.2% |
| Net margin | -2.3% | 13.6% | -40.4% | -1.9% |
| Net income | -$5.34M | $31.11M | -$103.27M | -$5.14M |
| EPS (Diluted) | -$0.02 | $0.61 | -$1.41 | -$0.14 |
| Operating cash flow | $67.99M | $41.80M | $13.90M | $43.86M |
| Free cash flow | $67.70M | $41.73M | $12.46M | $42.98M |
| Cash & equivalents | $184.84M | $29.64M | $230.52M | $72.93M |
| Total assets | $376.56M | $216.30M | $726.16M | $399.48M |
| Total liabilities | $343.95M | $85.96M | $362.11M | $347.39M |
| Shareholders' equity | $32.61M | $130.34M | $364.05M | $52.45M |
| Return on year-end equity | -16.4% | 23.9% | -28.4% | -9.8% |
| Shares outstanding | 265.42M | 50.41M | n/a | 37.23M |
Revenue, most recent five fiscal years
| Fiscal year | Akebia Therapeutics, Inc. | Puma Biotechnology, Inc. | Schrodinger, Inc. | Harrow, Inc. |
|---|---|---|---|---|
| Latest | $236.20M Ended 2025-12-31 | $228.37M Ended 2025-12-31 | $255.87M Ended 2025-12-31 | $272.30M Ended 2025-12-31 |
| 1 year earlier | $160.18M Ended 2024-12-31 | $230.47M Ended 2024-12-31 | $207.54M Ended 2024-12-31 | $199.61M Ended 2024-12-31 |
| 2 years earlier | $194.62M Ended 2023-12-31 | $235.64M Ended 2023-12-31 | $216.67M Ended 2023-12-31 | $130.19M Ended 2023-12-31 |
| 3 years earlier | $292.48M Ended 2022-12-31 | $228.03M Ended 2022-12-31 | $180.96M Ended 2022-12-31 | $88.59M Ended 2022-12-31 |
| 4 years earlier | $211.65M Ended 2021-12-31 | $253.16M Ended 2021-12-31 | $137.93M Ended 2021-12-31 | $72.48M Ended 2021-12-31 |